Kaleido Biosciences Inc
OTC:KLDO

Watchlist Manager
Kaleido Biosciences Inc Logo
Kaleido Biosciences Inc
OTC:KLDO
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: $4.3k

Operating Margin

-7 940.9%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-7 940.9%
=
Operating Income
$-87.7m
/
Revenue
$1.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-7 940.9%
=
Operating Income
$-87.7m
/
Revenue
$1.1m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Kaleido Biosciences Inc
OTC:KLDO
4.3k USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
530.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP
Loading...
CH
Novartis AG
SIX:NOVN
222.3B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
267.5B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.2B EUR
Loading...

Market Distribution

Lower than 96% of companies in the United States of America
Percentile
4th
Based on 14 112 companies
4th percentile
-7 940.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Kaleido Biosciences Inc
Glance View

Market Cap
4.3k USD
Industry
Pharmaceuticals

Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. The company is headquartered in Bedford, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-02-28. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. The company is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development as prevention of infections caused by multi-drug resistant (MDR) bacteria. Nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers, as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.

KLDO Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-7 940.9%
=
Operating Income
$-87.7m
/
Revenue
$1.1m
How has Operating Margin changed over time?

Over the last 2 years, Kaleido Biosciences Inc’s Operating Margin has increased from -31 544% to -7 940.9%. During this period, it reached a low of -31 544% on Jun 30, 2020 and a high of -6 470.1% on Mar 31, 2021.

Back to Top